Traded Jun 11, 2026 · Filed Jun 12, 2026
Johnson & Johnson's Chief TO and Risk Officer sold $2.41M of Johnson & Johnson shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$2,411,500
Shares × reported transaction price
58 days after results of Apr 14, 2026, 34 days before results of Jul 15, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $238.33 on Jun 11, 2026, within 5% of its 52-week high, after a 5% rise over the previous 30 trading days
52-week range $149.79 (Jun 20, 2025) to $248.56 (Mar 2, 2026), 90% of the way up, from 251 adjusted closes. 30 trading days earlier: $227.35 on Apr 29, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Tremfya on May 28, 2026, 14 days before this trade.
New use approved (efficacy supplement). Active ingredient: Guselkumab. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -1.9% | -1.4% | -0.5% |
| 30 days | +4.8% | 0.0% | +4.8% |
| 90 days | +13.0% | +0.8% | +12.2% |
Past results only. Not a forecast.
Congress tradeSits on House Ways and Means, Health5 different filers disclosed JNJ within 90 days. Disclosed 27 days after the transaction; reported as an official range, not an exact amount.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
